var data={"title":"Clodronate (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clodronate (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5921?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clodronate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clodronate (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152938\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bonefos;</li>\n      <li>Clasteon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152955\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152941\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bonefos: Multiple infusions: 300 mg over at least 2 hours once daily; continue until plasma calcium levels return to normal (usually 2 to 5 days); treatment duration should not exceed 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clasteon (discontinued product [DSC]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single infusion: 1,500 mg over at least 4 hours as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Multiple infusions: 300 mg over 2 to 6 hours once daily; treatment duration should not exceed 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Regardless of infusion method, plasma calcium levels usually normalize within 2 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Recommended daily maintenance dose following calcium normalization with IV therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bonefos, Clasteon [DSC]: Range: 1,600 mg to 2,400 mg given in a single dose or in 2 divided doses; maximum recommended daily dose: 3,200 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Note:</b> Re-treatment: Limited data suggest that patients who develop hypercalcemia following discontinuation of therapy or during oral therapy may be retreated with Bonefos or Clasteon [DSC] at a higher oral dosage (up to 3,200 mg/day) or by IV infusion with Clasteon [DSC] (1,500 mg as single dose or 300 mg once daily) or Bonefos (300 mg once daily).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Osteolytic bone metastases:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bonefos: Multiple infusions: 300 mg over at least 2 hours once daily; treatment duration should not exceed 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clasteon [DSC]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single infusion: 1,500 mg over at least 4 hours as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Multiple infusions: 300 mg over 2 to 6 hours once daily; treatment duration should not exceed 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bonefos: Initial: 1,600 mg/day; may be increased to a maximum of 3,200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Clasteon [DSC]: Recommended daily maintenance dose following IV therapy: Range: 1,600 mg to 2,400 mg given in a single dose or in 2 divided doses; maximum recommended daily dose: 3,200 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Breast cancer, adjuvant therapy (off-label use):</b> Oral: 1,600 mg daily for 2 to 3 years (CCO/ASCO [Dhesy-Thind 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062976\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152942\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deterioration of renal function during IV therapy: Stop treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Clasteon [DSC]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum creatinine (S<sub>cr</sub>) &gt;5 mg/dL: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">S<sub>cr</sub> &ge;2.5 to 5 mg/dL: There are no specific dosage adjustments provided in manufacturer's labeling; however, the manufacturer recommends considering a dose reduction or withholding therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Bonefos:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">S<sub>cr</sub> &gt;5 mg/dL: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 to 80 mL/minute: Administer 75% to 100% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrC: 12 to 50 mL/minute: Administer 50% to 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;12 mL/minute: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: <b>Note:</b> Daily doses &gt;1,600 mg should not be used continuously.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Administer 50% of normal dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44519544\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, elimination is predominantly renal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6006757\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bonefos, Clasteon: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Intravenous:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bonefos: 60 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clasteon: 30 mg/mL (10 mL) [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217381\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152917\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Swallow whole. Patient should be instructed to stay upright (not lie down) for at least 30 minutes after ingestion and until after the first food of the day (to reduce esophageal irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bonefos: Administer with a glass of plain water at least 2 hours before or after food or other medication; if the daily dose is divided into 2 doses, the second dose should be administered at least 1 hour before or at least 2 hours after food/medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clasteon [DSC]: Administer with a glass of plain water at least 1 hour before or after food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse daily doses over at least 2 hours (Bonefos) or over 2 to 6 hours (Clasteon [DSC]); infuse single doses (Clasteon [DSC]) over at least 4 hours. Do not administer as bolus injection. Patients should be adequately hydrated with oral or IV fluids prior to infusion. Avoid extravasation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152916\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy:</b> Management of hypercalcemia of malignancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteolytic bone metastases:</b> Adjunct in the management of osteolysis due to bone metastases of malignant tumors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50404460\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Breast cancer (adjuvant therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50404599\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152905\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hepatic: Increased serum transaminases (postmenopausal osteopenic women: 18%; &gt;2 x ULN: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal disease (&le;10%; includes stomach pain), nausea (3%), diarrhea (2%), anorexia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Bone fracture (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Arthralgia (severe), bronchospasm (patients with aspirin-sensitive asthma), conjunctivitis, dysphagia, erythematous rash, femur fracture (atypical subtrochanteric and diaphyseal), hypersensitivity reactions (angioedema, dyspnea [in patients with aspirin-sensitive asthma], pruritus, respiratory disorder, skin rash, urticaria), hypophosphatemia (transient), increased liver enzymes, increased parathyroid hormone, leukemia (rare), maculopapular rash, mouth irritation, myalgia (severe), myelodysplasia (rare), ropharyngeal ulcer, ostealgia (severe), osteonecrosis (jaw or external auditory canal), proteinuria, renal failure, renal insufficiency, uveitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152920\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to clodronate, other bisphosphonates, or any component of the formulation; severe GI tract inflammation; renal impairment (serum creatinine &gt;5 mg/dL, SI 440 micromole/L); concomitant use with other bisphosphonates; pregnancy or breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152903\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority of cases have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3 to 5 years) therapy may be at an increased risk. Patients with thigh or groin pain should be assessed for atypical fracture. Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Strict adherence to dosing instructions is advised. Use with caution in patients unable to remain upright for &ge;30 minutes after ingestion and/or with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use and evaluate patient if new or worsening symptoms (eg, dyspepsia, dysphagia, retrosternal pain), develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Risk of hypocalcemia (often asymptomatic) may be associated with both oral and intravenous use, however chelation of serum calcium observed with intravenous administration can further increase this risk. Interrupting the infusion or reducing the oral dose may be necessary. Correction of severe or symptomatic hypocalcemia may require calcium supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions including dyspnea or other respiratory disorders have been observed; use caution in patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Conjunctivitis, uveitis, scleritis, and episcleritis have been observed with bisphosphonates; patients with complicated or severe infection may require therapy discontinuation and should be referred for ophthalmic evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include dental surgery, cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids), poor oral hygiene, and comorbid disorders (anemia, coagulopathy, infection, preexisting oral disease). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. Other risk factors for MRONJ include dentoalveolar surgery (eg, tooth extraction, dental implants), and preexisting inflammatory dental disease. Risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with intravenous antiresorptive use compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer&rsquo;s labeling states that during therapy, invasive dental procedures and dental surgery should be avoided if possible; for patients requiring dental procedures, there are no data suggesting whether bisphosphonate discontinuation decreases ONJ risk; the start of a new course of IV treatment should be delayed if there are unhealed open soft-tissue lesions in the mouth; for both IV and oral therapy, consider interrupting treatment until condition resolves and contributing risk factors are mitigated. The AAOMS authors suggest that, if conditions permit, therapy initiation of intravenous antiresorptive agents for cancer therapy should be delayed until optimal dental health is attained. In oncology patients already receiving intravenous bisphosphonates, dental procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in renal impairment; may aggravate renal function particularly with IV doses exceeding maximum recommended doses and/or too rapid infusion. Close monitoring of serum creatinine and BUN and adequate hydration are required with renal impairment. Interrupt infusion in patients experiencing deteriorating renal function during therapy. Dose reductions are required for moderate or severe impairment. Use is contraindicated when serum creatinine &gt;5 mg/dL (SI 440 micromole/L).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[Canadian Boxed Warning]</b>: <b>Clasteon injection should not be administered as a bolus injection; may precipitate acute renal failure as well as severe local reactions and thrombophlebitis.</b> Dilute prior to use; ensure adequate hydration prior to and during infusion. Avoid infiltration/extravasation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299064\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152907\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8774&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Magaldrate; Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estramustine: Clodronate may increase the serum concentration of Estramustine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152934\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids, calcium, iron, and multivalent cations) may reduce the absorption of bisphosphonates as much as 60%. Management: Administer with a glass of plain water at least 2 hours (Bonefos) or 1 hour (Clasteon) before or after food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152923\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated during pregnancy. Adverse events have been observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011). Available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Levy 2009; Stathopoulos 2011). However until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20471796\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breastfeeding is contraindicated by the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">It is not known if clodronate is present in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152911\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes including calcium (daily during IV therapy), phosphorous, magnesium, and potassium; monitor for hypocalcemia for at least 2 weeks after therapy; serum creatinine, BUN, CBC with differential, hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152915\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Calcium (total): Adults: 9 to 11 mg/dL (SI: 2.05 to 2.54 mmol/L), may slightly decrease with aging; Phosphorus: 2.5 to 4.5 mg/dL (SI: 0.81 to 1.45 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152902\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate that lowers serum calcium by inhibition of bone resorption via actions on osteoclasts or on osteoclast precursors; may also have indirect inhibitory effects through osteoblastic cells, which control recruitment and activity of osteoclasts. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152919\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of calcium-lowering effects: IV: Within 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of calcium-lowering effects: 5 days to 3 weeks following discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~20 L; 20% of absorbed clodronate is bound to bone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Variable (2% to 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 1% to 3% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Oral: ~6 hours; IV: 13 hours (serum); prolonged in bone tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 80% of absorbed dose as unchanged drug); feces (as unabsorbed drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152924\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actabone (ID);</li>\n      <li>Bonefos (AE, AT, BE, BG, BH, BR, CH, CN, CO, CZ, DK, EE, ES, FI, GB, GR, HK, HN, HR, ID, IE, IL, KW, LU, LV, MT, MX, MY, NL, NO, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Clasteon (IE, IT, MT, TR);</li>\n      <li>Clodron (DE);</li>\n      <li>Moticlod (VN);</li>\n      <li>Ostac (BR);</li>\n      <li>Osteobon (SY);</li>\n      <li>Sinclote (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonefos (clodronate disodium) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clasteon (clodronate disodium) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clasteon (clodronate disodium) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline.<i>J Clin Oncol</i>. 2017;35(18):2062-2081.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/28618241/pubmed\" target=\"_blank\" id=\"28618241\">28618241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Katz M, and Crowley J, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/16000365/pubmed\" target=\"_blank\" id=\"16000365\">16000365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filleul O, Crompot E, and Saussez S, &quot;Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,&quot; <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/20508948/pubmed\" target=\"_blank\" id=\"20508948\">20508948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA, Yee GC, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. <i>J Clin Oncol</i>. 2007;25(17):2464-2472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/17515569/pubmed\" target=\"_blank\" id=\"17515569\">17515569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo JC, O'Ryan FS, Gordon NP, et al, &quot;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&quot; <i>J Oral Maxillofac Surg</i>, 2010, 68(2):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/19772941/pubmed\" target=\"_blank\" id=\"19772941\">19772941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maerevoet M, Martin C, and Duck L, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo;<i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/16003838/pubmed\" target=\"_blank\" id=\"16003838\">16003838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx RE, Sawatari Y, Fortin M, et al, &quot;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&quot; <i>J Oral Maxillofac Surg</i>, 2005, 63(11):1567-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/16243172 /pubmed\" target=\"_blank\" id=\"16243172 \">16243172 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. <i>J Oral Maxillofac Surg</i>. 2007;65(3):415-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/17307586/pubmed\" target=\"_blank\" id=\"17307586\">17307586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon RE, Bouquot JE, Glueck CJ, et al, &ldquo;Osteonecrosis: A Multifactorial Etiology,&rdquo; <i>J Oral Maxillofac Surg</i>, 2004, 62(7):904-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/15244000/pubmed\" target=\"_blank\" id=\"15244000\">15244000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pecherstorfer M, Schilling T, Janisch S, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. <i>J Nucl Med</i>. 1993;34(7):1039-1044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/8315476/pubmed\" target=\"_blank\" id=\"8315476\">8315476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tarassoff P and Csermak K, &ldquo;Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients,&rdquo; <i>J Oral Maxillofac Surg</i>, 2003, 61(10):1238-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/14586868/pubmed\" target=\"_blank\" id=\"14586868\">14586868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Poznak CH, Temin S, Yee GC, et al; American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. <i>J Clin Oncol</i>. 2011;29(9):1221-1227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clodronate-united-states-not-available-drug-information/abstract-text/21343561/pubmed\" target=\"_blank\" id=\"21343561\">21343561</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8774 Version 113.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F152938\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F152955\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F152941\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062976\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F152942\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F44519544\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F6006757\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217381\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F152917\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F152916\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50404460\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50404599\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F152905\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152920\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152903\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299064\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F152907\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F152934\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F152923\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20471796\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F152911\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F152915\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152902\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F152919\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F152924\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8774|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clodronate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Clodronate (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}